Comparative Pharmacology
Head-to-head clinical analysis: MINOXIDIL versus TRANSDERM NITRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MINOXIDIL versus TRANSDERM NITRO.
MINOXIDIL vs TRANSDERM-NITRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Minoxidil is a potassium channel opener that hyperpolarizes vascular smooth muscle cells, leading to vasodilation. In hair follicles, it promotes hair growth by increasing blood flow and prolonging the anagen phase, possibly through stimulation of prostaglandin synthesis.
Nitroglycerin is converted to nitric oxide (NO), which activates guanylate cyclase, increasing cGMP in vascular smooth muscle, leading to vasodilation.
Oral: 5-40 mg/day in 1-2 divided doses, starting at 5 mg/day and titrating upward; Topical: 1 mL of 2% or 5% solution twice daily.
Initial dose 0.2-0.4 mg/hour transdermally once daily. Titrate to 0.4-0.8 mg/hour. Maximum 0.8 mg/hour.
None Documented
None Documented
Clinical Note
moderateMinoxidil + Etacrynic acid
"The risk or severity of adverse effects can be increased when Minoxidil is combined with Etacrynic acid."
Clinical Note
moderateMinoxidil + Furosemide
"The risk or severity of adverse effects can be increased when Minoxidil is combined with Furosemide."
Clinical Note
moderateMinoxidil + Bumetanide
"The risk or severity of adverse effects can be increased when Minoxidil is combined with Bumetanide."
Clinical Note
moderateMinoxidil + Travoprost
Terminal elimination half-life: 4.2 hours; clinical context: may be prolonged in renal impairment (up to 18 hours), requiring dose adjustment.
Terminal elimination half-life is approximately 1-4 minutes after IV administration due to rapid metabolism. After transdermal application, the apparent half-life is 3-4 hours due to continued absorption from the skin depot, resulting in a prolonged clinical effect.
Renal: 90% as unchanged drug and metabolites; fecal: 10% via bile.
Renal (primarily) and biliary; ~60-80% of the dose is excreted renally as metabolites, with <1% unchanged. Fecal excretion accounts for ~10-20%.
Category A/B
Category C
Vasodilator / Hair Growth Stimulant
Vasodilator
"Minoxidil may increase the hypotensive activities of Travoprost."